🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in India / NCT07083947
Active, not recruiting Not applicable

Effect of Herbal Compositions on Body Weight, Body Composition and Metabolic Health in Overweight Subjects

NCT07083947 · tracked via the Priya Life Science India tracker
Sponsor
ApexCPG LLC
Phase
Not applicable
Started
2025-07-16
Last updated
2025-12-01

Condition(s) studied

Healthy Participants

Investigational drug(s) / intervention(s)

CL19183CL24212Placebo

CL19183: One capsule taken orally each morning after breakfast with water for 16 weeks

CL24212: One capsule taken orally each morning after breakfast with water for 16 weeks

Placebo: One capsule taken orally each morning after breakfast with water for 16 weeks

Study summary

The Purpose of the study is to evaluate the efficacy of herbal composition CL19183 and CL24212 on body weight, body composition and metabolic health in overweight subjects.

Eligibility

Sex
ALL
Min age
22 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * 1\. Healthy male and female subjects aged between 25-55 years with body mass index (BMI) of 25-29.9 kg/m2. 2\. Subjects with sedentary lifestyle, no regular athletic or sports activities. 3. Subjects willing to participate in walking-exercise (5 days a week, 30 min per day) over study duration. 4\. Subjects with normal thyroid hormone profile. 5. Subjects agreed to consume recommended standard diet. 6. Subjects who are willing to abstain from alcohol, coffee, tea, cola, energy drinks \& chocolate for at least 24 hrs. prior to visits and final visit. 7\. Subjects who are non-smokers. 8. Subject agrees to maintain diet tracker. 9. Subject considered generally healthy as per health history and routine clinical investigations during screening. 10\. Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera®, or double-barrier and have a negative pregnancy test at the screening visit. 11\. Ability to understand the risks/benefits of the protocol and willing to sign the written informed consent. Exclusion Criteria: * 1\. Subjects who were taking medications which affect the metabolic rate (e.g. antidepressants, beta-blockers, hormones, etc.). 2\. Subjects on weight loss practices, usage of weight reduction supplements/nutrition products will be excluded. 3\. Subjects underwent treatment for COVID 19 within last 3 months or tested positive during the study will be excluded. 4\. Subjects participated in any weight loss programs within 3 months. 5. Subjects who are diabetic and/or hypertensive. 6. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, malignancies. 7\. Subjects taking medications for or suffering from a medical condition that could impact results related to metabolism (e.g., thyroid disorders, diabetes, mental disorders such as anxiety or depression, heart disease, arthritis, cancer). 8\. Subjects with HIV Positive. 9. Female subjects, who are pregnant, breast feeding or planning to become pregnant during the study. 10\. Subjects having history of psychiatric disorder that may impair the ability of subjects to provide written informed consent. 11\. Any other condition that, in the opinion of the investigator, would adversely affect the subject's ability to complete the study or its measures. 12\. Use of nutritional supplements (e.g., creatine, protein drinks, amino acids, or vitamins) or ergogenic aids and caffeinated and not caffeinated thermogenics within 30 days prior to the study. 13\. Subjects who are participated or currently participating in another clinical trial within 30 days prior to screening.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Swaroop Rani Hospital, Motilal Nehru Medical College Allahābād Uttar Pradesh

More ApexCPG LLC trials in India

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07083947 on ClinicalTrials.gov ↗ ← All trials in India